{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:55:10Z","timestamp":1788965710813,"version":"build-2803163510"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is one of the severe cutaneous adverse drug reactions (SCARs) with high mortality rate and variable long term sequelae, especially in thyroid dysfunction and thyroiditis. In this article, we review clinical course, culprit drugs, onset of diagnosis, and type of thyroid dysfunction in DRESS patients. There were a total of 51 cases including 12 children (aged less than 18 years old) and 39 adults from our review. The most common thyroid dysfunction was Hashimoto\u2019s thyroiditis (41\/51=80.4%) including anti-thyroid antibody positive (29\/51=56.9%), possible\/compatible with Hashimoto\u2019s thyroiditis (12\/51=23.5%) both in the children (n=12) and adult (n=39), Graves\u2019 disease\/hyperthyroidism (7\/51=13.7%) and non-specific hypothyroidism (3\/51=5.9%), respectively. The most common culprit drugs and onset of thyroid dysfunction after DRESS diagnosis in children aged less than 18 years include antiepileptic drugs (phenytoin, phenobarbital, carbamazepine) (range 0\u20138 months, median 2 months) and sulfa groups (sulfasalazine, sulfamethoxazole, sulfonamide) (range 1\u20134 months, median 2 months). Data of prevalence, type, and clinical course of thyroid dysfunction from DRESS is important for clinicians to recognize for monitoring its sequelae and provide plans for treatment.<\/jats:p>","DOI":"10.1515\/jpem-2021-0685","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T14:05:59Z","timestamp":1643983559000},"page":"567-575","source":"Crossref","is-referenced-by-count":14,"title":["Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature"],"prefix":"10.1515","volume":"35","author":[{"given":"Therdpong","family":"Tempark","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawatchai","family":"Deekajorndech","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susheera","family":"Chatproedprai","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vichit","family":"Supornsilchai","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriwan","family":"Wananukul","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics , Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2023033121124495614_j_jpem-2021-0685_ref_001","doi-asserted-by":"crossref","unstructured":"Jantararoungtong, T, Tempark, T, Koomdee, N, Medhasi, S, Sukasem, C. Genotyping HLA alleles to predict the development of severe cutaneous adverse drug reactions (SCARs): state-of-the-art. Expet Opin Drug Metabol Toxicol 2021;17:1049\u201364. https:\/\/doi.org\/10.1080\/17425255.2021.1946514.","DOI":"10.1080\/17425255.2021.1946514"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_002","doi-asserted-by":"crossref","unstructured":"Bocquet, H, Bagot, M, Roujeau, JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250\u20137. https:\/\/doi.org\/10.1016\/s1085-5629(96)80038-1.","DOI":"10.1016\/S1085-5629(96)80038-1"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_003","doi-asserted-by":"crossref","unstructured":"Sukasem, C, Tempark, T. Pharmacogenomics: a new approach for preventing severe cutaneous adverse drug reactions. In: Pathak, Y, editor. Genomics-driven healthcare: trends in disease prevention and treatment. Singapore: Springer Nature; 2018:373\u2013409 pp.","DOI":"10.1007\/978-981-10-7506-3_18"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_004","doi-asserted-by":"crossref","unstructured":"Kim, GY, Anderson, KR, Davis, DMR, Hand, JL, Tollefson, MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature. J Am Acad Dermatol 2020;83:1323\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.081.","DOI":"10.1016\/j.jaad.2020.03.081"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_005","doi-asserted-by":"crossref","unstructured":"Teo, RY, Tay, YK, Tan, CH, Ng, V, Oh, DC. Presumed dapsone-induced drug hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis. Ann Acad Med Singapore 2006;35:833\u20136.","DOI":"10.47102\/annals-acadmedsg.V35N11p833"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_006","doi-asserted-by":"crossref","unstructured":"Ye, YM, Kim, JE, Kim, JH, Choi, GS, Park, HS. Propylthiouracil-induced DRESS syndrome confirmed by a positive patch test. Allergy 2010;65:407\u20139. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02183.x.","DOI":"10.1111\/j.1398-9995.2009.02183.x"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_007","doi-asserted-by":"crossref","unstructured":"Shaughnessy, KK, Bouchard, SM, Mohr, MR, Herre, JM, Salkey, KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol 2010;62:315\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.046.","DOI":"10.1016\/j.jaad.2009.05.046"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_008","doi-asserted-by":"crossref","unstructured":"Tung, Y, Escutia, B, Blanes, M, Navarrro, M, Pujol, C. Sulfasalazine-induced hypersensitivity syndrome associated with human herpesvirus 6 reactivation and induction of antiphospholipid syndrome. Actas Dermosifiliogr 2011;102:537\u201340. https:\/\/doi.org\/10.1016\/j.adengl.2010.12.002.","DOI":"10.1016\/j.adengl.2010.12.002"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_009","doi-asserted-by":"crossref","unstructured":"Mizumoto, K, Sumikawa, Y, Niihara, H, Morita, E. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol 2012;39:791\u20132. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01421.x.","DOI":"10.1111\/j.1346-8138.2011.01421.x"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_010","doi-asserted-by":"crossref","unstructured":"Cookson, H, Creamer, D, Walsh, S. Thyroid dysfunction in drug reaction with eosinophilia and systemic symptoms (DRESS): an unusual manifestation of systemic drug hypersensitivity. Br J Dermatol 2013;168:1130\u20132. https:\/\/doi.org\/10.1111\/bjd.12169.","DOI":"10.1111\/bjd.12169"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_011","doi-asserted-by":"crossref","unstructured":"Chen, YC, Chang, CY, Cho, YT, Chiu, HC, Chu, CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013;68:459\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2012.08.009.","DOI":"10.1016\/j.jaad.2012.08.009"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_012","doi-asserted-by":"crossref","unstructured":"Ushigome, Y, Kano, Y, Ishida, T, Hirahara, K, Shiohara, T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 2013;68:721\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2012.10.017.","DOI":"10.1016\/j.jaad.2012.10.017"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_013","doi-asserted-by":"crossref","unstructured":"Descamps, V. Drug reaction with eosinophilia and systemic symptoms and thyroiditis: human herpesvirus-6, the possible common link. Br J Dermatol 2013;169:952. https:\/\/doi.org\/10.1111\/bjd.12456.","DOI":"10.1111\/bjd.12456"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_014","doi-asserted-by":"crossref","unstructured":"Descamps, V, Ranger-Rogez, S. DRESS syndrome. Joint Bone Spine 2014;81:15\u201321. https:\/\/doi.org\/10.1016\/j.jbspin.2013.05.002.","DOI":"10.1016\/j.jbspin.2013.05.002"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_015","doi-asserted-by":"crossref","unstructured":"Minegaki, Y, Higashida, Y, Ogawa, M, Miyachi, Y, Fujii, H, Kabashima, K. Drug-induced hypersensitivity syndrome complicated with concurrent fulminant type 1 diabetes mellitus and Hashimoto\u2019s thyroiditis. Int J Dermatol 2013;52:355\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05213.x.","DOI":"10.1111\/j.1365-4632.2011.05213.x"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_016","doi-asserted-by":"crossref","unstructured":"Ito, K, Akita, Y, Ishida, N, Kasugai, C, Tamada, Y, Watanabe, D. Painless thyroiditis in drug-induced hypersensitivity syndrome with prolonged reactivation of herpesviruses. Int J Dermatol 2013;52:475\u20137. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05240.x.","DOI":"10.1111\/j.1365-4632.2011.05240.x"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_017","doi-asserted-by":"crossref","unstructured":"Singer, EM, Wanat, KA, Rosenbach, MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol 2013;149:494\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1949.","DOI":"10.1001\/jamadermatol.2013.1949"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_018","doi-asserted-by":"crossref","unstructured":"Kano, Y, Tohyama, M, Aihara, M, Matsukura, S, Watanabe, H, Sueki, H, et al.. Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol 2015;42:276\u201382. https:\/\/doi.org\/10.1111\/1346-8138.12770.","DOI":"10.1111\/1346-8138.12770"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_019","doi-asserted-by":"crossref","unstructured":"Sato, M, Mizuno, Y, Matsuyama, K, Shu, E, Kanoh, H, Suwa, T, et al.. Drug-induced hypersensitivity syndrome followed by subacute thyroiditis. Case Rep Dermatol 2015;7:161\u20135. https:\/\/doi.org\/10.1159\/000437251.","DOI":"10.1159\/000437251"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_020","unstructured":"Marchese, M, Leinung, M, Shawa, H. Drug-induced hypersensitivity reaction: a case of simultaneous thyroiditis and fulminant type 1 diabetes. Avicenna J Med 2017;7:67\u201370. https:\/\/doi.org\/10.4103\/ajm.AJM_124_16."},{"key":"2023033121124495614_j_jpem-2021-0685_ref_021","doi-asserted-by":"crossref","unstructured":"Matta, JM, Flores, SM, Cherit, JD. Drug reaction with eosinophilia and systemic symptoms (DRESS) and its relation with autoimmunity in a reference center in Mexico. An Bras Dermatol 2017;92:30\u20133. https:\/\/doi.org\/10.1590\/abd1806-4841.20175190.","DOI":"10.1590\/abd1806-4841.20175190"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_022","doi-asserted-by":"crossref","unstructured":"Deng, M, Wu, H, Yu, M, Tian, Y, Li, Y, Xiao, X. Co-occurrence of multiple endocrine abnormalities induced by the DIHS\/DRESS. Internet J Endocrinol 2019;2019:7959615. https:\/\/doi.org\/10.1155\/2019\/7959615.","DOI":"10.1155\/2019\/7959615"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_023","doi-asserted-by":"crossref","unstructured":"Chen, X, Cai, Y, Ge, X. Allopurinol-induced hypersensitivity syndrome followed by painless thyroiditis in a patient with asymptomatic hyperuricemia. Arch Med Sci 2020;16:1254\u20136. https:\/\/doi.org\/10.5114\/aoms.2020.97971.","DOI":"10.5114\/aoms.2020.97971"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_024","doi-asserted-by":"crossref","unstructured":"Truong, K, Kelly, S, Bayly, A, Smith, A. Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis. BMJ Case Rep 2021;14:e242240. https:\/\/doi.org\/10.1136\/bcr-2021-242240.","DOI":"10.1136\/bcr-2021-242240"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_025","doi-asserted-by":"crossref","unstructured":"Sandhu, S, Neema, S, Vashisht, D, Venugopal, R, Sengupta, P, Radhakrishnan, S. Drug reaction with eosinophilia and systemic symptoms: a single center descriptive observational study. Dermatol Ther 2021;34:e14670. https:\/\/doi.org\/10.1111\/dth.14670.","DOI":"10.1111\/dth.14670"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_026","doi-asserted-by":"crossref","unstructured":"Shiiya, C, Ouchi, T, Funakoshi, T, Amagai, M, Takahashi, H. Autoimmune and inflammatory diseases occur in cases of drug-induced hypersensitivity syndrome but not in suspected cases. J Dermatol 2021;48:e45\u20136. https:\/\/doi.org\/10.1111\/1346-8138.15639.","DOI":"10.1111\/1346-8138.15639"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_027","doi-asserted-by":"crossref","unstructured":"Gupta, A, Eggo, MC, Uetrecht, JP, Cribb, AE, Daneman, D, Rieder, MJ, et al.. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;51:56\u201367. https:\/\/doi.org\/10.1038\/clpt.1992.8.","DOI":"10.1038\/clpt.1992.8"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_028","doi-asserted-by":"crossref","unstructured":"Brown, RJ, Rother, KI, Artman, H, Mercurio, MG, Wang, R, Looney, RJ, et al.. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009;145:63\u20136. https:\/\/doi.org\/10.1001\/archdermatol.2008.521.","DOI":"10.1001\/archdermatol.2008.521"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_029","doi-asserted-by":"crossref","unstructured":"Shastry, V, Betkerur, J. Hypothyroidism as a late manifestation of drug hypersensitivity syndrome. Indian J Dermatol 2010;55:405\u20136. https:\/\/doi.org\/10.4103\/0019-5154.74574.","DOI":"10.4103\/0019-5154.74574"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_030","doi-asserted-by":"crossref","unstructured":"Coughlin, CC, Jen, MV, Boos, MD. Drug hypersensitivity syndrome with prolonged course complicated by parvovirus infection. Pediatr Dermatol 2016;33:e364\u20135. https:\/\/doi.org\/10.1111\/pde.13007.","DOI":"10.1111\/pde.13007"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_031","doi-asserted-by":"crossref","unstructured":"Morita, C, Yanase, T, Shiohara, T, Aoyama, Y. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep 2018. https:\/\/doi.org\/10.1136\/bcr-2018-225528.","DOI":"10.1136\/bcr-2018-225528"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_032","doi-asserted-by":"crossref","unstructured":"Oberlin, KE, Rahnama-Moghadam, S, Alomari, AK, Haggstrom, AN. Drug reaction with eosinophilia and systemic symptoms: pediatric case series and literature review. Pediatr Dermatol 2019;36:887\u201392. https:\/\/doi.org\/10.1111\/pde.13949.","DOI":"10.1111\/pde.13949"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_033","doi-asserted-by":"crossref","unstructured":"Onuma, H, Tohyama, M, Imagawa, A, Hanafusa, T, Kobayashi, T, Kano, Y, et al.. Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research; Japanese Dermatological association. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab 2012;97:E2277\u201381. https:\/\/doi.org\/10.1210\/jc.2012-2054.","DOI":"10.1210\/jc.2012-2054"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_034","doi-asserted-by":"crossref","unstructured":"Park, BK, Coleman, JW, Kitteringham, NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581\u201390. https:\/\/doi.org\/10.1016\/0006-2952(87)90706-4.","DOI":"10.1016\/0006-2952(87)90706-4"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_035","doi-asserted-by":"crossref","unstructured":"Cribb, AE, Nuss, CE, Alberts, DW, Lamphere, DB, Grant, DM, Grossman, SJ, et al.. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996;9:500\u20137. https:\/\/doi.org\/10.1021\/tx950167j.","DOI":"10.1021\/tx950167j"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_036","unstructured":"Kubow, S, Wells, PG. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol Pharmacol 1989;35:504\u201311."},{"key":"2023033121124495614_j_jpem-2021-0685_ref_037","doi-asserted-by":"crossref","unstructured":"Picard, D, Janela, B, Descamps, V, D\u2019Incan, M, Courville, P, Jacquot, S, et al.. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010;2:46ra62. https:\/\/doi.org\/10.1126\/scitranslmed.3001116.","DOI":"10.1126\/scitranslmed.3001116"},{"key":"2023033121124495614_j_jpem-2021-0685_ref_038","doi-asserted-by":"crossref","unstructured":"Tohyama, M, Hashimoto, K, Yasukawa, M, Kimura, H, Horikawa, T, Nakajima, K, et al.. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934\u201340. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08167.x.","DOI":"10.1111\/j.1365-2133.2007.08167.x"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0685\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T10:49:44Z","timestamp":1680346184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0685\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,5,25]]}},"alternative-id":["10.1515\/jpem-2021-0685"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2021-0685","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}